BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

ViroPharma Incorporated (VPHM) Investigated by Federal Trade Commission Over Possible Unfair Competition Methods


4/12/2012 7:10:26 AM

Philadelphia Business Journal by John George, Senior Reporter

ViroPharma Inc. said it has received a notification that the Federal Trade Commission is conducting an investigation into whether the company has engaged in unfair methods of competition with respect to its antibiotic product Vancocin.

“The existence of an investigation does not indicate that the FTC has concluded that ViroPharma has violated the law and the company does not believe that it has engaged in unfair methods of competition,” ViroPharma (NASDAQ:VPHM) officials said in a statement

The Exton, Pa., biopharmaceutical company said it intends to cooperate with the investigation.

Word of the FTC probe comes at the same time the Food and Drug Administration approved three companies’ applications to market a generic for Vancocin. The FDA also on Tuesday denied ViroPharma’s petition seeking to block the agency method’s for evaluating generic competitors and ruled the company is not entitled to three additional years of market exclusivity after filing a supplemental new drug application for Vancocin.

ViroPharma said it believes the FDA violated its own regulations by allowing generic drug companies to submit the results of in vitro (test tube) bioequivalence testing without requiring a waiver for in vivo (human) testing.

Vancocin is used to treat a common and potentially life-threatening hospital-acquired infection known as clostridium difficile-associated pseudomembranous colitis, also known as C-diff.

ViroPharma’s stock price plunged 22 percent Tuesday, closing at $22.44 per share.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->